AU2021369409A1 - Anti-sars-cov-2 antigen antibodies and related compositions and methods - Google Patents

Anti-sars-cov-2 antigen antibodies and related compositions and methods Download PDF

Info

Publication number
AU2021369409A1
AU2021369409A1 AU2021369409A AU2021369409A AU2021369409A1 AU 2021369409 A1 AU2021369409 A1 AU 2021369409A1 AU 2021369409 A AU2021369409 A AU 2021369409A AU 2021369409 A AU2021369409 A AU 2021369409A AU 2021369409 A1 AU2021369409 A1 AU 2021369409A1
Authority
AU
Australia
Prior art keywords
polypeptide
seq
set forth
amino acid
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2021369409A
Other languages
English (en)
Other versions
AU2021369409A9 (en
Inventor
Peter J. R. EBERT
Amy Gilbert
Gladys KEITANY
Mark Klinger
Ben RUBIN
Erik Yusko
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adaptive Biotechnologies Corp
Original Assignee
Adaptive Biotechnologies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adaptive Biotechnologies Corp filed Critical Adaptive Biotechnologies Corp
Publication of AU2021369409A1 publication Critical patent/AU2021369409A1/en
Publication of AU2021369409A9 publication Critical patent/AU2021369409A9/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pulmonology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2021369409A 2020-10-30 2021-10-29 Anti-sars-cov-2 antigen antibodies and related compositions and methods Abandoned AU2021369409A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063108158P 2020-10-30 2020-10-30
US63/108,158 2020-10-30
US202063108791P 2020-11-02 2020-11-02
US63/108,791 2020-11-02
US202063112096P 2020-11-10 2020-11-10
US63/112,096 2020-11-10
US202163190097P 2021-05-18 2021-05-18
US63/190,097 2021-05-18
PCT/US2021/057452 WO2022094343A1 (en) 2020-10-30 2021-10-29 Anti-sars-cov-2 antigen antibodies and related compositions and methods

Publications (2)

Publication Number Publication Date
AU2021369409A1 true AU2021369409A1 (en) 2023-06-15
AU2021369409A9 AU2021369409A9 (en) 2024-10-10

Family

ID=81384373

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021369409A Abandoned AU2021369409A1 (en) 2020-10-30 2021-10-29 Anti-sars-cov-2 antigen antibodies and related compositions and methods

Country Status (8)

Country Link
US (1) US20230382979A1 (enExample)
EP (1) EP4237443A4 (enExample)
JP (1) JP2023548471A (enExample)
AU (1) AU2021369409A1 (enExample)
BR (1) BR112023008365A2 (enExample)
CA (1) CA3200263A1 (enExample)
IL (1) IL302460A (enExample)
WO (1) WO2022094343A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120981481A (zh) * 2023-01-10 2025-11-18 萨那生物技术股份有限公司 Cd19特异性抗体构建体以及它们的组合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3538557A4 (en) * 2016-11-08 2020-11-18 Ablexis, LLC ANTI-CD47 ANTIBODY
WO2019075433A1 (en) * 2017-10-13 2019-04-18 Adimab, Llc ANTIBODIES AGAINST SYNCYTIAL RESPIRATORY VIRUS AND METHODS FOR THEIR GENERATION AND USE
CR20220552A (es) * 2020-04-02 2023-01-17 Regeneron Pharma Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno

Also Published As

Publication number Publication date
CA3200263A1 (en) 2022-05-05
JP2023548471A (ja) 2023-11-17
EP4237443A4 (en) 2025-06-04
US20230382979A1 (en) 2023-11-30
WO2022094343A1 (en) 2022-05-05
IL302460A (en) 2023-06-01
BR112023008365A2 (pt) 2023-12-12
AU2021369409A9 (en) 2024-10-10
EP4237443A1 (en) 2023-09-06

Similar Documents

Publication Publication Date Title
US20240174745A1 (en) Antibody Constructs for CLDN18.2 and CD3
KR20180037950A (ko) 메소텔린 및 cd3에 결합하는 이중특이적 항체 작제물
TW202311292A (zh) Ｃｄｈ３與ｃｄ３之雙特異性抗體構築體
CN110088131B (zh) 抗chikv抗体及其用途
US20240228596A1 (en) Pan-specific corona virus binders
US20230357364A1 (en) Covid-19 antibodies and uses thereof
WO2023222825A1 (en) Sarbecovirus spike s2 subunit binders
JP2026081251A (ja) 抗ｔｒｅｍ－１抗体およびその使用
CA3207548A1 (en) Sarbecovirus binders
TW202432602A (zh) 運鐵蛋白受體結合蛋白
US20230382979A1 (en) Anti-sars-cov-2 antigen antibodies and related compositions and methods
WO2022136685A1 (en) Antibody compositions for treatment of corona virus infection
KR20230098335A (ko) 클리핑 비율이 감소된 항원 결합 도메인
US20260116983A1 (en) Anti-Urokinase-Type Plasminogen Activator Receptor Antibodies and Methods of Use
WO2024058987A2 (en) Polypeptides effective against multiple coronaviruses
US20240391980A1 (en) Anti-Human Astrovirus Antibodies and Related Compositions and Methods
CA3107192C (en) Antibody constructs for cldn18.2 and cd3
WO2025083216A1 (en) Antibodies specific for the spike protein of sars cov-2 coronavirus
WO2024259378A1 (en) T cell engager masking molecules
WO2023025813A1 (en) Neutralizing antibodies directed to sars-cov-2 spike protein
WO2024192280A2 (en) Antibodies against orthohantaviruses
CN117836321A (zh) 抗牛痘病毒抗原抗体以及相关组合物和方法
WO2026059969A1 (en) Human pd-1 and ctla4 neutralizing vhh antibodies and methods of use thereof

Legal Events

Date Code Title Description
SREP Specification republished
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period